HepCBC Mission Statement

HepCBC is a non-profit organization run by and for people infected and affected by hepatitis C. Our mission is to provide education, prevention and support to those living with HCV.

The Best of the Week to You: Feb 9 - Feb 16, 2018

What We Do

Hot Off The Press!

Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 (Reuters) - A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc. The verdict had been the largest ever in a U.S. patent case but U.S. District Judge Leonard Stark in Wilmington, Delaware, on Friday ruled Merck’s patent was invalid. He said it did not meet a requirement that it disc

The Week in Review: February 9 – February 16, 2018

Friday, February 16, 2018 News Recap: HCV & Heart Disease: Evolving Recognition of Chronic Hepatitis C Infection as a Modifiable Risk Factor for CVD. This article examines the evidence for clinical and subclinical cardiovascular diseases in chronic hepatitis c infection, as well as the effect of treatment on cardiovascular outcomes. News from Around the World: NZ: Thousands of Hepatitis C sufferers unaware a cure is within reach. A Hepatitis...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, researchers from Boston Medical Center, Massachusetts General Hospital (MGH) and Stanford University found that this expanded screening would increase life expectancy and quality of life while remaining cost-effective. The Centers fo

Evolving Recognition of Chronic Hepatitis C Infection as a Modifiable Risk Factor for CVD

Many studies have identified extrahepatic manifestation of chronic hepatitis C virus (HCV) infection, including associations with lymphoproliferative disorders, diabetes mellitus, and renal disease. Increasingly, data have amassed exploring whether HCV infection acts as an independent risk factor for cardiovascular diseases. Evidence for Subclinical Cardiovascular Diseases in Chronic Hepatitis C Infection A recent review by Babiker et al published in the